Seres Therapeutics, Inc. (MCRB)
After hours:
- Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., February 03, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on February 1, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 48,750 shares of its common stock to eleven new employees, consisting of stock options to purchase an aggregate of 32,500 shares of common stock and restricted stock units ("RSUs"), cov
- Simply Wall St.
Seres Therapeutics' (NASDAQ:MCRB) investors will be pleased with their respectable 70% return over the last three years
The last three months have been tough on Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shareholders, who have seen the share...
- Business Wire
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress
CAMBRIDGE, Mass., January 05, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors. Dr. Fraser will begin serving on Seres’ Board, effective immediately.
